# Sickle Cell Acute Chest Syndrome

Treat suspected acute chest syndrome as a potentially progressive pulmonary emergency: admit, establish oxygenation and respiratory trajectory, obtain chest imaging and transfusion readiness, begin analgesia, cautious hydration, lung expansion therapy, and antibiotics, then escalate promptly for refractory hypoxemia or multilobar deterioration.

**Clinical question:** How should physicians diagnose, stabilize, and escalate initial treatment for acute chest syndrome in patients with sickle cell disease?

Updated: 2026-09-15T21:30:33.935343+00:00

## What matters in practice
- Diagnose ACS when a patient with sickle cell disease has a new pulmonary infiltrate or radiodensity plus respiratory symptoms and/or fever; obtain chest imaging early because presentation may evolve during a pain admission. [12][16][21]
- Admit patients with ACS, maintain oxygen saturation at or above 95%, avoid hyperhydration, provide incentive spirometry, and crossmatch early for possible simple or exchange transfusion. [22]
- Start antimicrobial treatment directed at community-acquired respiratory pathogens, provide adequate analgesia and supplemental oxygen, and use modest rather than excessive IV fluid replacement. [3][12][17]
- Escalate to exchange transfusion for extensive bilateral pulmonary disease, hypoxemia not corrected by supplemental oxygen, or rapid clinical deterioration; partial exchange is particularly relevant when anemia is mild but respiratory status worsens. [12][17]
- In adults, ACS can progress to respiratory failure requiring mechanical ventilation; early ICU involvement is appropriate for worsening oxygenation, increasing work of breathing, or rapidly progressive infiltrates. [21]

## Identify ACS early and determine the need for critical care

Do not attribute new respiratory findings during vaso-occlusive pain solely to opioid use or atelectasis.

Treat ACS as present when a patient with sickle cell disease develops a new pulmonary infiltrate involving at least one complete lung segment consistent with alveolar consolidation, excluding atelectasis, plus chest pain, temperature above 38.5°C, tachypnea, wheezing or rales, or cough. A practical emergency definition also includes a new chest-imaging radiodensity with respiratory symptoms and/or fever. [16][21]

Obtain pulse oximetry, focused respiratory examination, and chest radiography at presentation. Chest radiography is the customary first-line imaging test; consider chest CT when the diagnosis remains uncertain or further imaging is needed after the initial radiograph. Lung ultrasound is a promising adjunct but does not replace clinical reassessment in a deteriorating patient. [21]

Admit patients with ACS. Obtain early hematology input and involve intensive care for increasing oxygen requirement, worsening work of breathing, refractory hypoxemia, extensive bilateral infiltrates, or rapid clinical decline. ACS is a leading cause of ICU admission in adults with sickle cell disease and may progress to respiratory failure requiring mechanical ventilation in 20% of adult patients. [2][21]
- During an admission for vaso-occlusive pain, reassess promptly for ACS when fever, cough, chest pain, dyspnea, tachypnea, wheeze, crackles, or oxygen desaturation develops; ACS may arise after hospitalization rather than only at presentation. [12]
- Do not limit the differential to infection: recognized triggers include infectious pneumonia, pulmonary fat embolism, and multifactorial or initially unclear processes. [12][21]
- For concurrent fever in a child with sickle cell disease, draw blood cultures when feasible but administer broad-spectrum antibiotics within 30 minutes of presentation without waiting for cultures. [22]

*Initial disposition and transfusion-escalation decisions in ACS. [12][17][21][22]*

| Clinical finding | Immediate action | What changes next |
| --- | --- | --- |
| New infiltrate or radiodensity with respiratory symptoms and/or fever | Admit; initiate oxygenation assessment, chest imaging review, analgesia, cautious fluids, lung expansion therapy, antibiotics, and transfusion preparation. [21][22] | Serial respiratory assessment determines whether supportive treatment is sufficient or transfusion support must be intensified. [17] |
| Hypoxemia corrected with supplemental oxygen without rapid deterioration | Maintain oxygen saturation at or above 95%; crossmatch and assess need for simple transfusion. [22] | Worsening oxygenation despite oxygen is an exchange-transfusion trigger. [17] |
| Extensive bilateral pulmonary disease, oxygen-refractory hypoxemia, or rapid clinical deterioration | Activate ICU and hematology/transfusion medicine pathways for exchange transfusion. [17] | Prepare for ventilatory support if respiratory failure evolves. [9][21] |
| Mild anemia with worsening respiratory status | Consider partial exchange transfusion rather than simple transfusion. [12] | Escalate without waiting for further radiographic progression if respiratory status is deteriorating. [12][17] |

## Build the initial workup around pulmonary severity and alternate causes

The first evaluation should establish ACS, identify a plausible precipitant, and prepare for transfusion escalation.

Obtain a chest radiograph in every patient with suspected ACS and compare it with prior imaging when available. A negative or limited initial study should not end evaluation when symptoms are evolving; repeat clinical assessment and pursue CT when additional imaging is required to clarify the pulmonary process. [21]

Order a type and crossmatch at admission because transfusion may be required as ACS progresses. In severe ACS, involve hematology and intensive care while transfusion planning is underway rather than reserving consultation until respiratory failure occurs. [22]

Use the clinical pattern to direct immediate parallel evaluation. Fever and a new infiltrate support infectious pneumonia requiring antibacterial coverage; wheeze or a suspected reactive-airway component supports nebulized therapy; chest, back, or abdominal pain and opioid exposure increase the need for lung expansion measures and careful analgesic reassessment. [12][17][22]
- Document oxygen requirement and response to supplemental oxygen; lack of correction is a defined escalation trigger for exchange transfusion. [17]
- Assess radiographic distribution: extensive bilateral pulmonary disease favors urgent exchange-transfusion planning. [17]
- When abdominal pain is prominent, assess for alternate sickle cell complications such as hepatic or splenic sequestration and cholecystitis rather than labeling all pain as vaso-occlusion. [16][22]

*Actionable etiologic patterns during the initial ACS evaluation. [12][16][17][21][22]*

| Pattern | Discriminator | Immediate management implication |
| --- | --- | --- |
| Infectious pulmonary process | Fever and new pulmonary infiltrate; atypical bacteria are recognized causes in children. [12] | Begin antibiotics covering community-acquired respiratory pathogens; do not defer treatment while awaiting diagnostic clarification. [17][22] |
| Pulmonary fat embolism or noninfectious ACS | ACS can be multifactorial or noninfectious, including pulmonary fat embolism. [12][21] | Prioritize respiratory trajectory, oxygen support, and early transfusion escalation if hypoxemia or infiltrates worsen. [17] |
| Reactive-airway contribution | Wheezing or a clinical reactive-airway component. [16][17] | Add nebulized bronchodilator therapy when a reactive-airway component is suspected. [17] |
| Pain-associated hypoventilation or atelectatic risk | Chest, back, or abdominal pain; opioid-treated vaso-occlusive episode. [22] | Optimize analgesia while using incentive spirometry, upright positioning, and early ambulation; avoid fluid excess. [22] |

## Start oxygen, analgesia, lung expansion, cautious fluids, and antibiotics concurrently

Initial therapy is multimodal because ACS often deteriorates through overlapping infection, pain, hypoventilation, and vaso-occlusion.

Provide supplemental oxygen and target an oxygen saturation of at least 95%. Failure of hypoxemia to correct with supplemental oxygen should prompt urgent escalation toward exchange transfusion and critical-care management rather than continued observation on the ward. [17][22]

Treat pain sufficiently to permit deep breathing, coughing, mobilization, and use of incentive spirometry. Acetaminophen, NSAIDs, and opioids may be used as needed within the patient's established pain plan; in pediatric vaso-occlusive events, scheduled acetaminophen and an NSAID alongside opioids are recommended. Prevent opioid-related constipation with polyethylene glycol 3350 when opioids are used. [17][22]

Use incentive spirometry and respiratory therapy early. One ACS protocol recommends 10 incentive-spirometry breaths every 2 hours while awake; for pain episodes involving the chest, back, or abdomen, maintain upright posture and encourage ambulation as soon as feasible to reduce pulmonary complications. [17][22]

Use oral hydration when tolerated and limit IV fluids to maintenance-level total fluid intake rather than hyperhydration. Excess hydration has been associated with increased ACS risk, while ACS management reviews support modest hydration as part of initial treatment. [12][22]

Start broad-spectrum antibacterial treatment for ACS and tailor subsequent therapy to the suspected community-acquired pulmonary pathogens and clinical course. Macrolide antibiotics are included in pediatric ACS management, reflecting the recognized role of atypical respiratory bacteria. [12][17][22]
- Add nebulized bronchodilators when wheezing or a reactive-airway component is present. [17]
- Use lung-protective ventilation if intubation is required for respiratory failure. [9]
- Avoid cold packs during vaso-occlusive pain treatment. [22]

*Core initial ACS treatment bundle and reassessment targets. [3][9][12][17][22]*

| Intervention | Operational approach | Escalation or monitoring target |
| --- | --- | --- |
| Oxygen | Give supplemental oxygen and maintain saturation at or above 95%. [22] | If hypoxemia is not corrected, arrange exchange transfusion and ICU-level management. [17] |
| Analgesia | Use acetaminophen, NSAID, and/or opioid therapy sufficient for pulmonary hygiene; individualize to the established plan when available. [17][22] | Reassess ventilation, sedation, mobility, and ability to use incentive spirometry. [22] |
| Fluids | Encourage oral intake; if IV fluids are needed, limit total intake to maintenance volumes. [22] | Avoid hyperhydration because it is associated with increased ACS risk. [22] |
| Respiratory therapy | Use incentive spirometry; one protocol uses 10 breaths every 2 hours while awake. [17] | Add nebulizers for suspected reactive-airway disease; escalate for worsening oxygenation or work of breathing. [17] |
| Antibiotics | Initiate broad-spectrum therapy for ACS, directed toward community-acquired pathogens; include macrolide coverage in pediatric management. [12][17][22] | Modify treatment as microbiologic and clinical information becomes available. [17] |

## Choose simple versus exchange transfusion by anemia and pulmonary trajectory

Transfusion decisions should track respiratory deterioration, not wait for established respiratory failure.

Crossmatch early and consider simple red cell transfusion as part of ACS management, particularly when anemia accompanies the pulmonary event. Reviews describe supplemental oxygen, modest hydration, antibiotics, and often simple transfusion as the core early regimen for pediatric ACS. [12][22]

Use partial or automated red cell exchange when respiratory disease is escalating despite initial measures. Specific triggers include extensive bilateral pulmonary disease, hypoxemia not corrected with supplemental oxygen, and rapid clinical deterioration. In a patient with mild anemia, defined in pediatric guidance as hemoglobin greater than 9 g/dL, but worsening respiratory status, partial exchange transfusion is preferred over relying on simple transfusion. [12][17]

Automated red cell exchange rapidly removes sickled erythrocytes while replacing donor cells and can reduce hemoglobin S without the cumulative iron burden of chronic simple transfusion. Severe ACS is an established indication; coordinate the procedure with hematology, transfusion medicine, and critical care according to local apheresis capability. [6][17][22]

If ventilatory failure develops, use lung-protective mechanical ventilation and continue urgent transfusion-based reduction of sickling burden. Do not treat mechanical ventilation as a substitute for exchange-transfusion assessment in rapidly progressive ACS. [9][17][21]
- Consult hematology and intensive care for severe ACS while arranging crossmatched blood; this is specifically recommended when exchange transfusion may be needed. [22]
- Use clinical worsening, oxygenation response, and radiographic extent to select escalation; ACS severity is not defined by a single presenting feature. [17][21]
- Patients with sickle cell disease can develop ACS across genotypes; do not withhold ACS evaluation because the patient does not have homozygous sickle cell disease. [21]

*Transfusion selection for initial ACS management. [6][12][17][22]*

| Clinical situation | Transfusion approach | Rationale and next step |
| --- | --- | --- |
| ACS requiring transfusion support without listed severe pulmonary features | Consider simple red cell transfusion after crossmatching. [12][22] | Continue close oxygenation and respiratory reassessment; escalate if disease progresses. [17] |
| Hemoglobin greater than 9 g/dL with deteriorating respiratory status | Use partial exchange transfusion. [12] | Avoid reliance on simple transfusion alone when anemia is mild but pulmonary compromise is worsening. [12] |
| Extensive bilateral disease, oxygen-refractory hypoxemia, or rapid deterioration | Perform exchange transfusion. [17] | Manage in conjunction with hematology, transfusion medicine, and ICU. [17][22] |
| Severe ACS where automated exchange is available | Use automated red cell exchange when appropriate. [6] | The procedure rapidly reduces circulating sickled cells and can limit iron accumulation in chronic use. [6] |

## Use the hospitalization to reduce recurrent ACS risk

Before discharge, link the acute episode to disease-modifying follow-up and a documented pulmonary-risk plan.

After stabilization, review hydroxyurea use and adherence with the patient's sickle cell clinician. Hydroxyurea has demonstrated effectiveness in preventing recurrent ACS in adults and children; recurrent ACS despite disease-modifying therapy may also lead to consideration of chronic transfusion strategies or hematopoietic stem cell transplantation in appropriately selected patients. [5]

Provide a discharge plan that specifies when to return for fever, cough, chest pain, dyspnea, or worsening pain, and ensure hematology follow-up. For pain management after discharge, provide appropriate prescriptions and education rather than allowing gaps in analgesic access that can promote repeated emergency presentations. [22]

For patients with recurrent pulmonary events, reassess modifiable contributors identified during the admission, including inadequate pain control, lack of incentive spirometry during pain episodes, fluid excess, and untreated reactive-airway symptoms. [17][22]
- Document whether the episode required simple transfusion, partial exchange, automated exchange, noninvasive respiratory support, or intubation to inform future emergency plans. [6][9][12]
- Encourage early evaluation for recurrent respiratory symptoms because ACS can develop during otherwise routine vaso-occlusive admissions. [12]

## References
1. Case Report Automated red cell exchange in acute sickle cell crises — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2531137926002014
2. The many facets of cardiopulmonary complications in sickle cell disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S003719632600051X
3. [PDF] Acute chest syndrome in sickle cell disease - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/am/pii/S0735675722003850
4. Hemoglobin SD Disease - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/hemoglobin-sd-disease
5. Standard management of sickle cell disease complications ☆ : Hematology/Oncology and Stem Cell Therapy — journals.lww.com — https://journals.lww.com/hosct/fulltext/2020/13020/standard_management_of_sickle_cell_disease.8.aspx
6. A Study of Red Cell Exchange in Patients of Sickle Cell... : Global Journal of Transfusion Medicine — journals.lww.com — https://journals.lww.com/gjtm/fulltext/2024/09010/a_study_of_red_cell_exchange_in_patients_of_sickle.6.aspx
7. 20th Annual Sickle Cell & Thalassaemia Conference — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/bjh.70197
8. Impact of blood transfusion therapy - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.23877
9. Acute chest syndrome from sickle cell disease successfully ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/aor.14761
10. Acute chest syndrome: sickle cell disease - Paul - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2011.01647.x
11. Antenatal medication management for women with sickle‐cell ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/pmf2.70039
12. How I treat acute chest syndrome in children with sickle cell disease — ashpublications.org — https://ashpublications.org/blood/article/117/20/5297/21182/How-I-treat-acute-chest-syndrome-in-children-with
13. Novel Therapeutic Approaches in Sickle Cell Disease — ashpublications.org — https://ashpublications.org/hematology/article/2002/1/10/18600/Novel-Therapeutic-Approaches-in-Sickle-Cell
14. Emerging concepts in sickle cell disease acute chest syndrome — ashpublications.org — https://ashpublications.org/bloodrci/article/2/2/100060/566434/Emerging-concepts-in-sickle-cell-disease-acute
15. American Society of Hematology 2019 guidelines for sickle cell ... — ashpublications.org — https://ashpublications.org/bloodadvances/article/3/23/3867/429210/American-Society-of-Hematology-2019-guidelines-for
16. [PDF] 14 February 2025 Re: Cover Letter for ClinicalTrials.gov ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/03/NCT02187003/Prot_000.pdf
17. [PDF] Feasibility Study of Unfractionated Heparin in Acute Chest ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/93/NCT02098993/Prot_SAP_000.pdf
18. Anaesthesia for peculiar cells'a century of sickle cell disease — www.bjanaesthesia.org — https://www.bjanaesthesia.org/article/S0007-0912(17)35985-8/fulltext
19. Improving Care for Children With Sickle Cell Disease/Acute Chest ... — publications.aap.org — https://publications.aap.org/pediatrics/article/127/2/e480/65236/Improving-Care-for-Children-With-Sickle-Cell
20. NeoReviews™ - AAP Publications — publications.aap.org — https://publications.aap.org/neoreviews/issue-pdf/821830
21. High risk and low prevalence diseases: Acute chest syndrome in sickle cell disease - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/35717760
22. Acute complications in children with sickle cell disease: Prevention and management - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900682
23. Annals of Emergency Medicine — www.annemergmed.com — https://www.annemergmed.com/article/S0196-0644(15)00618-6/pdf
24. [PDF] BMT CTN 1503 STRIDE - ClinicalTrials.gov — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/65/NCT02766465/Prot_SAP_ICF_000.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.